RhoA: A therapeutic target for chronic myeloid leukemia

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Molli, Poonam R ^a,b   Pradhan, Madhura B ^a,c   Advani, Suresh H ^a,d   Naik, Nishigandha R ^a,c  

^a TATA MEMORIAL HOSPITAL   (India)

^b RUTGERS UNIVERSITY   (United States)

^c Piramal Enterprises Limited   (India)

^d JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Actin; Chronic myeloid leukemia (CML); N formyl methionyl leucyl phenylalanine (fMLP); Polymorphonuclear leukocytes (PMNL); Rhogtpases; Signal transduction

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACTIN; ANTISENSE OLIGONUCLEOTIDE; CHOLECYSTOKININ OCTAPEPTIDE; EXOENZYME C3; F ACTIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GUANOSINE TRIPHOSPHATASE; IMATINIB; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PHOSPHODIESTERASE; RAC1 PROTEIN; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; AMIDE; BOTULINUM TOXIN; EXOENZYME C3, CLOSTRIDIUM BOTULINUM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PYRIDINE DERIVATIVE;

ACTIN POLYMERIZATION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NEUTROPHIL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL CULTURE; CELL STRAIN HL 60; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MYELOID LEUKEMIA; TUMOR CELL LINE;

ACTINS; ADP RIBOSE TRANSFERASES; AMIDES; BLOTTING, WESTERN; BOTULINUM TOXINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; GTP PHOSPHOHYDROLASES; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; NEUTROPHILS; PYRIDINES; RHOA GTP-BINDING PROTEIN;

EID: 84858734287     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-16     Document Type: Article

References (55)

1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985, 315:550-554. 10.1038/315550a0, 2989692.
2. Zingde S. The neutrophil in chronic myeloid leukaemia: molecular analysis of chemotaxis, endocytosis and adhesion. Cancer J 1998, 11:167-175.
3. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997, 11:2295-2322. 10.1101/gad.11.18.2295, 9308960.
4. Naik NR, Bhisey AN, Advani SH. Flow cytometric studies on actin polymerization in PMN cells from chronic myeloid leukemia (CML) patients. Leuk Res 1990, 14:921-930. 10.1016/0145-2126(90)90183-A, 2259229.
5. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998, 10:123-130. 10.1016/S0955-0674(98)80095-1, 9484604.
6. Tarachandani A, Advani SH, Bhisey AN. Chronic myeloid leukemia granulocytes have lower amounts of cytoplasmic actin. Leuk Res 1993, 17:833-838. 10.1016/0145-2126(93)90148-E, 8412295.
7. Ridley AJ. Historical overview of Rho GTPases. Methods Mol Biol 2011, 827:3-12. e-pub.
8. Naik NR, Advani SH, Bhisey AN. PMN cells from chronic myeloid leukemia (CML) patients show defective chemotaxis in remission. Leuk Res 1989, 13:959-965. 10.1016/0145-2126(89)90002-7, 2607777.
9. Heisterkamp N, Voncken JW, Senadheera D, Gonzalez-Gomez I, Reichert A, Haataja L, Reinikainen A, Pattengale PK, Groffen J. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood 2000, 96:2226-2232.
10. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. Embo J 1993, 12:1533-1546. 413366, 8467803.
11. Salgia R, Brunkhorst B, Pisick E, Li JL, Lo SH, Chen LB, Griffin JD. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995, 11:1149-1155.
12. Hernandez-Alcoceba R, del Peso L, Lacal JC. The Ras family of GTPases in cancer cell invasion. Cell Mol Life Sci 2000, 57:65-76. 10.1007/s000180050499, 10949581.
13. Hammond KD, Savage N, Littlewood M. Rhythmic patterns in the expression of the ras oncogene in proliferating and differentiating erythroleukaemia cells. Cell Biol Int 2000, 24:529-537. 10.1006/cbir.2000.0567, 10924226.
14. Sasaki AT, Chun C, Takeda K, Firtel RA. Localized Ras signaling at the leading edge regulates PI3K, cell polarity, and directional cell movement. J Cell Biol 2004, 167:505-518. 10.1083/jcb.200406177, 2172490, 15534002.
15. Kato M, Yamaguchi T, Tachibana A, Kimura H. Differential role of an atypical protein kinase C, PKC zeta, in regulation of human eosinophil and neutrophil functions. Int Arch Allergy Immunol 2005, 137(Suppl 1):27-34.
16. Chodniewicz D, Zhelev DV. Chemoattractant receptor-stimulated F-actin polymerization in the human neutrophil is signaled by 2 distinct pathways. Blood 2003, 101:1181-1184. 10.1182/blood-2002-05-1435, 12393389.
17. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997, 390:632-636. 10.1038/37656, 9403696.
18. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 1999, 147:1009-1022. 10.1083/jcb.147.5.1009, 2169355, 10579721.
19. Radhika V, Thennarasu S, Naik NR, Kumar A, Advani SH, Bhisey AN. Granulocytes from chronic myeloid leukemia (CML) patients show differential response to different chemoattractants. Am J Hematol 1996, 52:155-164. 10.1002/(SICI)1096-8652(199607)52:3<155::AID-AJH4>3.0.CO;2-S, 8756080.
20. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000, 19:3013-3020. 10.1038/sj.onc.1203621, 10871853.
21. Matos P, Skaug J, Marques B, Beck S, Verissimo F, Gespach C, Boavida MG, Scherer SW, Jordan P. Small GTPase Rac1: structure, localization, and expression of the human gene. Biochem Biophys Res Commun 2000, 277:741-751. 10.1006/bbrc.2000.3743, 11062023.
22. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004, 23:9369-9380. 10.1038/sj.onc.1208182, 15516977.
23. Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene 2002, 286:155-174. 10.1016/S0378-1119(02)00426-2, 11943472.
24. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 2002, 277:10678-10682. 10.1074/jbc.M111369200, 11788600.
25. Song Y, Wong C, Chang DD. Overexpression of wild-type RhoA produces growth arrest by disrupting actin cytoskeleton and microtubules. J Cell Biochem 2000, 80:229-240.
26. Naik N, Rigaut JP, Advani S, Bhisey A. Differences in the microtubule organization between normal and cml granulocytes after stimulation with chemotactic peptide. Cell Biol Int 2000, 24:135-144. 10.1006/cbir.1999.0491, 10772774.
27. Radhika V, Naik NR, Advani SH, Bhisey AN. Actin polymerization in response to different chemoattractants is reduced in granulocytes from chronic myeloid leukemia patients. Cytometry 2000, 42:379-386. 10.1002/1097-0320(20001215)42:6<379::AID-CYTO1005>3.0.CO;2-Q, 11135292.
28. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002, 2:133-142. 10.1038/nrc725, 12635176.
29. Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004, 1705:121-132.
30. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 2000, 149:775-782. 10.1083/jcb.149.4.775, 2174558, 10811819.
31. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991, 51:3602-3609.
32. Ridley AJ. The GTP-binding protein Rho. Int J Biochem Cell Biol 1997, 29:1225-1229. 10.1016/S1357-2725(97)00052-6, 9451818.
33. Ridley AJ. Rho proteins and cancer. Breast Cancer Res Treat 2004, 84:13-19. 10.1023/B:BREA.0000018423.47497.c6, 14999150.
34. Simpson KJ, Dugan AS, Mercurio AM. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 2004, 64:8694-8701. 10.1158/0008-5472.CAN-04-2247, 15574779.
35. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999, 81:682-687. 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B, 10328216.
36. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003, 83:861-870.
37. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 2005, 27:602-613. 10.1002/bies.20238, 15892119.
38. Faried A, Nakajima M, Sohda M, Miyazaki T, Kato H, Kuwano H. Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma. Eur J Surg Oncol 2005, 31:410-414. 10.1016/j.ejso.2004.12.014, 15837049.
39. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 2002, 87:635-644. 10.1038/sj.bjc.6600510, 2364248, 12237774.
40. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995, 269:1270-1272. 10.1126/science.7652575, 7652575.
41. Kovary K, Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 1991, 11:4466-4472. 361310, 1908553.
42. Liu SY, Yen CY, Yang SC, Chiang WF, Chang KW. Overexpression of Rac-1 small GTPase binding protein in oral squamous cell carcinoma. J Oral Maxillofac Surg 2004, 62:702-707. 10.1016/j.joms.2004.02.002, 15170282.
43. Burstein ES, Hesterberg DJ, Gutkind JS, Brann MR, Currier EA, Messier TL. The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors. Oncogene 1998, 17:1617-1623. 10.1038/sj.onc.1202067, 9794239.
44. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, et al. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997, 272:13-16. 10.1074/jbc.272.1.13, 8995216.
45. Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S, Tybulewicz VL, Peschel C, Duyster J. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem 2002, 277:12437-12445. 10.1074/jbc.M112397200, 11790798.
46. Korus M, Mahon GM, Cheng L, Whitehead IP. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene 2002, 21:4601-4612. 10.1038/sj.onc.1205678, 12096337.
47. Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem cells 2003, 21:315-321. 10.1634/stemcells.21-3-315, 12743326.
48. Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, Sondek J, Caligiuri MA, Der CJ. Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. J Biol Chem 2001, 276:27145-27151. 10.1074/jbc.M103565200, 11373293.
49. Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV, Ozer HL, Whitehead IP. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 2008, 27:2064-2071. 10.1038/sj.onc.1210841, 2676674, 17922031.
50. Daubon T, Chasseriau J, Ali AE, Rivet J, Kitzis A, Constantin B, Bourmeyster N. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs. Oncogene 2008, 27:2673-2685. 10.1038/sj.onc.1210933, 18059343.
51. Unwin RD, Sternberg DW, Lu Y, Pierce A, Gilliland DG, Whetton AD. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. J Biol Chem 2005, 280:6316-6326. 10.1074/jbc.M410598200, 15569670.
52. Burthem J, Rees-Unwin K, Mottram R, Adams J, Lucas GS, Spooncer E, Whetton AD. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. Leukemia 2007, 21:1708-1714. 10.1038/sj.leu.2404762, 17554385.
53. Mulloy JC, Cnacelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010, 115:936-947. 10.1182/blood-2009-09-198127, 2817638, 19965643.
54. Boyum A. Separation of blood leucocytes, granulocytes and lymphocytes. Tissue Antigens 1974, 4:269-274.
55. Cook Dye exclusion method: Viability Measurements in Mammalian Cell Systems. Analytical Biochemistry 1989, 179:1-7. 10.1016/0003-2697(89)90191-7, 2667390, Cook.